News and Announcements
Altech Extends Closing Date of Its Share Purchase Plan
- Published May 30, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Altech Chemicals Limited (ASX:ATC) advices that is has extended the Closing Date of its Share Purchase Plan (SPP) to Wednesday June 7 2017.
KEY TAKEAWAYS:
- Existing eligible shareholders of Altech have the opportunity to subscribe to a maximum of $15,000 of new shares and a minimum amount of $1,000 of new shares, via the SPP.
- Shares issued under the SPP will be priced at a 5% discount to the volume-weighted average price of Altech shares as traded on the Australian Securities Exchange over the 5 days up to, and including, the day on which the SPP offer closes, rounded down to the nearest half-cent.
- Altech will announce the final issue price for the SPP shares after the offer closes.
Under the SPP rules, shareholders who were recorded on the share register at 5 May 2017 with a registered address in Australia or New Zealand are eligible to participate.
Each eligible shareholder is entitled to apply for up to $15,000 of new fully paid ordinary shares of the Company without incurring any brokerage or other transaction costs. All new shares issues under the SPP will rank equally with existing ordinary shares of the Company.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
